Single domain antibodies for cancer therapy, Institut Curie
Summary
USPTO granted Patent US12594302B2 to Institut Curie covering fully humanized anti-FGFR4 single domain antibodies (sdAbs), functionalized drug nanocarriers, and compositions for cancer therapy. The patent includes 24 claims and covers nucleic acids, vectors, host cells, and immune cells comprising said sdAbs. The invention relates to FGFR4-targeted therapies for treating cancer.
What changed
USPTO granted Patent US12594302B2 to Institut Curie on April 7, 2026. The patent covers fully humanized anti-FGFR4 single domain antibodies (sdAbs) and variants thereof, including functionalized drug nanocarriers, nucleic acids, vectors, host cells, and immune cells comprising said sdAbs. The application (No. 17925411, filed May 20, 2021) contains 24 claims related to cancer therapy compositions.
Patent owners and licensees may enforce exclusive rights against potential infringers developing similar FGFR4-targeted cancer therapies. Competitors should review the patent claims to assess potential licensing needs or design-around requirements before developing competing anti-FGFR4 antibody products. The patent provides Institut Curie with market exclusivity for the claimed antibody compositions and therapeutic uses.
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Single domain antibodies and their use in cancer therapies
Grant US12594302B2 Kind: B2 Apr 07, 2026
Assignee
Institut Curie
Inventors
Sandrine Moutel, Franck Perez, Michele Bernasconi, Nagjie Laila Alijaj, Zélia Gouveia
Abstract
The present application relates to fully humanized anti-FGFR4 single domain antibodies (sdAbs) and variants thereof. The present invention further relates to functionalized drug nanocarriers, nucleic acids, vectors, host cells, immune cells comprising said sdAbs, and compositions comprising thereof, as well as their use for therapy.
CPC Classifications
C07K 16/2863 A61K 40/31
Filing Date
2021-05-20
Application No.
17925411
Claims
24
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.